Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 6 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| PROTEIN DESIGN LABS INC/DE | 650,000 | reported | 01 Oct 2008 | tx 2+775,000 |
| BIOGEN INC. | 29,175 | reported | 09 Jul 2008 | tx 60+231,499−130,615 |
| Nuvation Bio Inc. | 25,000 | reported | 10 Feb 2021 | tx 3+55,000−25,000 |
| Kura Oncology, Inc. | 23,983 | reported | 09 Dec 2025 | tx 15+258,182−32,682 |
| Forte Biosciences, Inc. | 7,500 | reported | 04 Oct 2019 | tx 9+304,226 |
| IMMUNIC, INC. | 4,500 | reported | 13 Sept 2018 | tx 8+337,614−177,443 |
| Receptos, Inc. | 0 | reported | 27 Aug 2015 | tx 12+329,725−1,356,991 |
| Gossamer Bio, Inc. | 0 | reported | 19 Mar 2026 | tx 48+18,108,607−7,430,410 |
| Somaxon Pharmaceuticals, Inc. | 0 | reported | 06 Mar 2013 | tx 8+210,028−27,974 |
| AMBIT BIOSCIENCES CORP | 0 | reported | 10 Nov 2014 | tx 9+28,000−187,266 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 544,500 | — | deriv |
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 437,500 | — | deriv |
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 544,500 | — | deriv |
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 650,000 | — | deriv |
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 325,000 | — | deriv |
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 47,000 | — | deriv |
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 43,500 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 1,680,000 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 1,540,000 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 1,312,500 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 437,500 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 544,500 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 544,500 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 650,000 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 325,000 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 47,000 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 43,500 | — | deriv |
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 1,680,000 | — | deriv |
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 1,540,000 | — | deriv |
| 19 Mar 2026 | OTHER | Gossamer Bio, Inc. | 1,312,500 | — | deriv |
| 02 Jan 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 280,000 | 0.00 USD | |
| 02 Jan 2026 | GRANT_AWARD | Gossamer Bio, Inc. | 1,680,000 | 0.00 USD | deriv |
| 09 Dec 2025 | EXERCISE | Kura Oncology, Inc. | 10,000 | 3.12 USD | |
| 09 Dec 2025 | SALE | Kura Oncology, Inc. | 10,000 | 10.98 USD | |
| 01 Oct 2025 | GRANT_AWARD | Gossamer Bio, Inc. | 437,500 | 0.00 USD |
3 purchases reported after at least 12 months of silence — most recent on 15 Jul 2022.